Synergistic combination of PMBA and 5-fluorouracil (5-FU) in targeting mutant KRAS in 2D and 3D colorectal cancer cells.

Qayum, Arem; Magotra, Asmita; Shah, Syed Mohmad; Nandi, Utpal; Sharma, P R; Shah, Bhahwal Ali; Singh, Shashank Kumar

Qayum, Arem; Magotra, Asmita; Shah, Syed Mohmad; Nandi, Utpal; Sharma, P R; Shah, Bhahwal Ali; Singh, Shashank Kumar.

Afiliación

Qayum A; Cancer Pharmacology Division, Indian Institute of Integrative Medicine, CSIR, Jammu, 180001, India.
Magotra A; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India.
Shah SM; PK-PD, Toxicology and Formulation Division, Indian Institute of Integrative Medicine, CSIR, Jammu, 180001, India.
Nandi U; Sher-e-Kashmir University of Agricultural Sciences & Technology of Kashmir, Srinagar, 190001, India.
Sharma PR; PK-PD, Toxicology and Formulation Division, Indian Institute of Integrative Medicine, CSIR, Jammu, 180001, India.
Shah BA; Cancer Pharmacology Division, Indian Institute of Integrative Medicine, CSIR, Jammu, 180001, India.
Singh SK; Natural Product Microbes Division, Indian Institute of Integrative Medicine, CSIR, Jammu, 180001, India.

Heliyon ; 8(4): e09103, 2022 Apr.

Article en En | MEDLINE | ID: mdl-35445157

Palabras clave

5-fluorouracil; Colon cancer; Combination study; KRAS; PMBA; Pharmacokinetics; Spheroid-formation (colonospheres)

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: Heliyon Año: 2022 Tipo del documento: Article País de afiliación: India